- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Cell signalling

Cells in our body work together and respond to changes in their environment. Many proteins are involved in transmitting signals within and between cells. Disruptions to this signalling is the cause of many diseases.
Our research into cell signalling aims to understand how different signals are transmitted, and their relevance to disease.
Our cell signalling research
Our researchers are investigating cell signalling in healthy cells, to understand what goes wrong to cause disease.
Particular foci of our research are:
- Investigating proteins that enable cell signalling, and how these signals are switched off.
- Defining the cell signalling pathways that trigger cell death and inflammation.
- Understanding how cell signalling pathways are subverted in diseases such as cancer, immune disorders and infections.
- Developing new treatments for disease that target key signalling molecules.
What is cell signalling?
Our bodies are composed of billions of cells that work together. Each cell responds to external signals from other cells, and from its environment. Cell signalling refers to the translation of an external signal into a cell’s response.
External signals can include:
- Direct contact with other cells or structures.
- Molecules that are secreted by other cells.
- Viral or bacterial infections.
- Nutrients, toxins or other molecules present in the environment.
Cells can have many different responses to external signals. A few examples are:
- Growing or dividing, or stopping division.
- Becoming activated to perform a specific function (e.g. to kill bacteria or infected cells).
- Dying, or staying alive.
- Moving or changing shape.
- Secreting a substance.
A particular signal may elicit different responses in different cell types. A cell’s response to a signal may also depend on other signals the cell receives, or has previously received.
Cell signalling molecules
Most cell signalling relies on pathways of molecules signalling to each other to bring about a response.
A ‘signalling cascade’ describes one molecule signalling to several molecules, which then signal to several more, and so on. This results in an amplified and complex response to one initial signal.
Receptors
Most external signals do not enter the cell themselves, but bind to the cell surface, usually via a protein called a receptor. These cell surface receptors often span the outer membrane of the cell.
Receptors are specific for one, or a few substances, called ‘ligands’. When the receptor is bound by its specific ligand, it changes shape in a way that is transmits the signal across the cell membrane – like turning a key in a lock moves the latch on the other side of the door.
Ligands
Ligands are substances that specifically bind receptors. Many ligands are proteins, and fit precisely into specific receptors. Hormones and cytokines are common ligands for signalling between cells.
Kinases
When a ligand binds a receptor, it triggers changes within the cell that influence other signalling molecules. Many signalling pathways involve proteins called kinases. Kinases can exist in ‘on’ and ‘off’ states of activation. In some cases, a binding of a ligand to a receptor will switch on (activate) a kinase.
When switched on, kinases attach a phosphate group onto other molecules, especially other proteins, changing how those proteins function. The proteins then have their own influences on other molecules.
Transcription factors
Many signalling pathways influence which genes are switched on in a cell. This effect can be mediated via changes to transcription factors, proteins that bind to specific DNA sequences in the genome. A transcription factor binding to a gene begins the process of copying it into its RNA form, allowing production of a particular protein.
Cell death signalling
Many signalling pathways in humans involve specialised proteins. Cell death signalling pathways are an example of this. In apoptotic cell death, various cellular stresses or a specific ligand binding to a ‘death receptor’ trigger changes within the cell that activate caspases, proteins that demolish the cell in a tightly controlled way.
Switching off signals
Cells in our body are constantly barraged with different signals from their environment. These signals may be short-lived and change rapidly. Cells need to be able to switch off signalling pathways as rapidly as they were switched on.
Proteins have evolved that act as feedback inhibitors and specifically terminate a cell signalling pathway. These proteins can switch off kinases or other signalling proteins, or initiate the destruction of proteins produced when the signalling pathway began.
The SOCS protein family was discovered by our researchers. These proteins specifically turn off many different types of signals. Our research has demonstrated that in the immune system SOCS proteins are especially important at restraining inflammatory signals. Without SOCS proteins, inflammatory signalling is prolonged and can cause tissue damage.
Cell signalling and disease
When cells do not respond appropriately to their environment, or do not work cooperatively with other cells, disease can result. Problems in cell signalling underlie many diseases. Some examples of disrupted cell signalling in disease include:
- Cancer cells have constant activation of signalling pathways instructing the cells to grow and divide. This often occurs because of changes (mutations) in receptors, protein kinases or transcription factors that keep the proteins an active state.
- Some immunodeficiencies occur because immune cells lack the receptors for ligands that instruct immune cells to divide and develop, or lack the specific kinases that transmit these signals.
- Many viruses, such as hepatitis B, produce proteins that interfere with the host cell’s signalling pathways in ways that suppress the immune system and enhance viral reproduction.
Targeting cell signalling
Cell signalling influences how cells behave in health and disease. Many medicines work by adjusting cell signalling pathways, often stifling a key signalling protein.
Some treatments for disease work by preventing a ligand binding to its receptor. Medications that block cytokine signalling between immune cells are in clinical use to treat inflammatory conditions such as rheumatoid arthritis.
Many new anti-cancer therapies target kinases that give cancer cells the signals to divide.
Our medicinal chemistry researchers are using three-dimensional structures of cell signalling proteins to develop small molecules that can specifically block the proteins’ function.
Researchers:
A signalling molecule called interleukin-11 is a potential new target for anti-cancer therapies
A landmark discovery about how insulin docks on cells could help in the development of improved types of insulin for treating both type 1 and type 2 diabetes.
Since their discovery by Professor Donald Metcalf and his colleagues, CSFs have helped millions of cancer patients to survive the damage to bone marrow caused by high-dose chemotherapy.